Last reviewed · How we verify
Gamma Variant RBD-based ARVAC-CG vaccine
Gamma Variant RBD-based ARVAC-CG vaccine is a Biologic drug developed by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno. It is currently in Phase 2 development.
At a glance
| Generic name | Gamma Variant RBD-based ARVAC-CG vaccine |
|---|---|
| Sponsor | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gamma Variant RBD-based ARVAC-CG vaccine CI brief — competitive landscape report
- Gamma Variant RBD-based ARVAC-CG vaccine updates RSS · CI watch RSS
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno portfolio CI
Frequently asked questions about Gamma Variant RBD-based ARVAC-CG vaccine
What is Gamma Variant RBD-based ARVAC-CG vaccine?
Gamma Variant RBD-based ARVAC-CG vaccine is a Biologic drug developed by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno.
Who makes Gamma Variant RBD-based ARVAC-CG vaccine?
Gamma Variant RBD-based ARVAC-CG vaccine is developed by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno (see full Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno pipeline at /company/centro-de-educaci-n-medica-e-investigaciones-cl-nicas-norberto-quirno).
What development phase is Gamma Variant RBD-based ARVAC-CG vaccine in?
Gamma Variant RBD-based ARVAC-CG vaccine is in Phase 2.